HomeCompareCRRTF vs CL

CRRTF vs CL: Dividend Comparison 2026

CRRTF yields 370.37% · CL yields 2.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CRRTF wins by $6548.93M in total portfolio value
10 years
CRRTF
CRRTF
● Live price
370.37%
Share price
$0.54
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6548.97M
Annual income
$4,277,213,599.54
Full CRRTF calculator →
CL
CL
● Live price
2.44%
Share price
$85.23
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41.0K
Annual income
$5,451.69
Full CL calculator →

Portfolio growth — CRRTF vs CL

📍 CRRTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCRRTFCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CRRTF + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CRRTF pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CRRTF
Annual income on $10K today (after 15% tax)
$31,481.48/yr
After 10yr DRIP, annual income (after tax)
$3,635,631,559.61/yr
CL
Annual income on $10K today (after 15% tax)
$207.44/yr
After 10yr DRIP, annual income (after tax)
$4,633.94/yr
At 15% tax rate, CRRTF beats the other by $3,635,626,925.67/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CRRTF + CL for your $10,000?

CRRTF: 50%CL: 50%
100% CL50/50100% CRRTF
Portfolio after 10yr
$3274.51M
Annual income
$2,138,609,525.62/yr
Blended yield
65.31%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

CRRTF
No analyst data
Altman Z
0.4
Piotroski
7/9
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+8.5% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CRRTF buys
0
CL buys
0
No recent congressional trades found for CRRTF or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCRRTFCL
Forward yield370.37%2.44%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28.6%
Portfolio after 10y$6548.97M$41.0K
Annual income after 10y$4,277,213,599.54$5,451.69
Total dividends collected$6335.38M$18.1K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: CRRTF vs CL ($10,000, DRIP)

YearCRRTF PortfolioCRRTF Income/yrCL PortfolioCL Income/yrGap
1← crossover$47,737$37,037.04$11,014$313.84+$36.7KCRRTF
2$216,316$165,237.23$12,200$415.44+$204.1KCRRTF
3$931,231$699,772.79$13,607$553.09+$917.6KCRRTF
4$3,811,831$2,815,413.69$15,301$741.41+$3.80MCRRTF
5$14,849,130$10,770,471.55$17,374$1,002.00+$14.83MCRRTF
6$55,100,513$39,211,943.26$19,958$1,367.44+$55.08MCRRTF
7$194,941,986$135,984,437.60$23,243$1,887.87+$194.92MCRRTF
8$658,217,820$449,629,894.71$27,512$2,642.43+$658.19MCRRTF
9$2,123,140,341$1,418,847,273.99$33,197$3,759.22+$2123.11MCRRTF
10$6,548,973,765$4,277,213,599.54$40,973$5,451.69+$6548.93MCRRTF

CRRTF vs CL: Complete Analysis 2026

CRRTFStock

Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including MMPE and DuraPeel for the development of topicals containing cannabis and hemp. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; CTX-101, a Phase III topical formulation utilizing a corticosteroid in combination with MMPE technology to treat plaque psoriasis; CTX-102, a Phase I topical formulation utilizing MMPE technology to treat an undisclosed dermatological skin condition; and dermatology products in pre-clinical formulation utilizing MMPE technology for prescription treatments of skin diseases. Its non-prescription skincare products comprise skincare products, such as facial creams, cleansers, exfoliants, masks, serums, and suncare products for aging, acne, rosacea, pigmentation, dehydration, and sensitivity under the Laboratoire Dr Renaud brand; a line of dermocosmetic products for anti-aging medical procedures under the Pro-Derm brand; a line of products to target and treat various skincare concerns under the Alyria brand; and skincare products primarily for the Asian consumers under Dermazulene brand, as well as NCTF 135 HA, a skin revitalization solution primarily used for the improvement of skin quality and fine lines. The company has a development and licensing agreement with Sundial Growers Inc. to develop cannabis; a commercialization license agreement with Cantabria Labs Inc.; and a development and commercialization license agreement with Taro Pharmaceuticals Inc. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada.

Full CRRTF Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this CRRTF vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CRRTF vs SCHDCRRTF vs JEPICRRTF vs OCRRTF vs KOCRRTF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.